Bioinsider (@Bioinsider1) header
Bioinsider (@Bioinsider1) profile picture

We provide a quality, unbiased virtual platform for communication among the scientific community, policymakers & business leaders.

Joined May 2020
Photo by Bioinsider (@Bioinsider1)Photo by Bioinsider (@Bioinsider1)Photo by Bioinsider (@Bioinsider1)Photo by Bioinsider (@Bioinsider1)Photo by Bioinsider (@Bioinsider1)Photo by Bioinsider (@Bioinsider1)Photo by Bioinsider (@Bioinsider1)Photo by Bioinsider (@Bioinsider1)Photo by Bioinsider (@Bioinsider1)Photo by Bioinsider (@Bioinsider1)
Recently, we have seen more and more trials becoming virtual as the #pandemic advanced virtual trials more to the forefront. Find out more about ongoing virtual clinical trials here: bit.ly/3xwj1y2 #virtualtrials #clinicaltrials #decentralizedclinicaltrials
Are COVID-19 vaccine shots the only way to develop immunity? Scientists seem to disagree, considering how most pathogens get into our bodies, shots might not even be the best way. bit.ly/3wcq0fy #biotech #covid19 #pandemic #biologics #covidvaccines #SARSCoV2
1
2
A recent collaboration among IGM Bio, UTMB and UTHealth have resulted in an anti-SARS-CoV-2 IgM antibody that can be administered intranasally to treat and prevent COVID-19 and its variants of concern. go.nature.com/3uJ1Mba #biotech #covid19 #antibody #biologics #SARSCoV2
1
Although CRISPR is becoming increasingly synonymous with a disease-free future, issues related to the control of this technology could limit its future impact. Read more here: bit.ly/3fx45sb #CRISPR #genetherapy #geneediting #biologics #biopharma #patent #IP
COVID-19 vaccine makers are still pumping out new vaccines from all over the world. Let's take a look at what are out there and how they are compared to each other. bit.ly/3w10ARz #vaccine #covidvaccine #biotech #pharma
Recent research indicates that efforts to increase diversity in clinical trials have been less than ideal and virtual clinical trials may have come to the rescue. Read more here: bit.ly/3b9rOxw #clinicaltrials #virtualclinicaltrials #digitalhealth #biotech #pharma
AI has attracted interest from 82% of the #healthcare and #lifescience industries who said they want to fully embrace the new #tech in their business. Government #regulation in #AI is also emphasized as it is still a new technology. bit.ly/30IhDu1 #ArtificialIntelligence
Johnson & Johnson announced their new partnership with Merck to produce Covid-19 vaccines with the goal to produce 100 million doses by June. Teaming up for the common good! wapo.st/3cx6GRn #pandemic #sarscov2 #vaccines #biotherapeutics #biopharma #pharma #partnership
This one key ingredient is so crucial in the making of the mRNA vaccines for COVID-19. #Lipid #nanoparticiples help stabilize, protect and deliver the mRNA to make proteins. Read More Here: bit.ly/3vp7d0r #pandemic #sarscov2 #vaccines #biotech #nanoparticle
1
Upon hearing about Bionaut Labs' micro-robotic pills that guide the drug to the brain, Khosla Ventures has decided to join the bet. bit.ly/30G81Qz #drugdevelopment #venturecapitalism #innovation #biotechnology #biologics #biopharma #pharmaceuticals #neurology
We have seen the few key members of the vaccine race start distributing their candidate to the public, but where do the remaining candidates stand? Learn More Here: bit.ly/3ccS9dz #pandemic #sarscov2 #vaccines
Century Therapeutics is in the process of developing their own allogenic therapy drug, they have raised $160 million to fund their race to market. Read More Here: bit.ly/3t4hy02 #drugdevelopment
Coherus Biosciences has decided to enter the realm of drug development closing a deal with Junshi Biosciences for the rights to their immunotherapy drug to treat cancer. Learn More Here: bit.ly/3kJNtjd #cancer
1
Johnson & Johnson received FDA approval for their COVID-19 vaccine. This vaccine consists of one dose as opposed to two and is able to be stored at refrigerator temperature, offering a new hope and a simpler option for Americans. Read More Here: bit.ly/3kAmzdp #cancer
Centessa has acquired 10 biotech startups to run as subsidaries under their larger name. Each of these companies will focus on one medicine or disease as opposed to pipelines spanning across multiple areas of research. View Full Article Here: bit.ly/3qJ3jg8 #biotechs
Post acquistion, small biotechs have been found to have a decline in their innovation. Read more here: bit.ly/2NluIqd #bigpharma #innovation #biotechnology